Abstract: Methods and percutaneous devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via percutaneous carotid body ablation.

Abstract: Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.

Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.

Abstract: Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device that employs high intensity focused ultrasound. The high intensity focused ultrasound may be used for application of energy to modulate neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. The ultrasound transducer for delivering the energy may be located remotely from the desired treatment area. In particular embodiments, an ultrasound transducer may apply energy at one or more focal zones or focal points that target renal nerves.

Abstract: Computational systems may be provided to assist with compression garment recommendations. A measurement of a person's body part may be received, and a compression expected to be applied may be computed. The expected compression may be based upon an arm measurement and upon a known relationship between a size of the garment, such as a stretched circumference, and the compression applied to an object that stretches the garment to that circumference. Graphs and formulas may be used to represent physical properties of a compression garment by assigning compression levels for ranges of relevant circumferences for a multitude of points along a limb. Information about needs of a patient, patient's condition, compression sensitivity, desired compression class, or desired use may be considered as part of a computational analysis to assist in fitting garments. The disclosed recommendation systems may assist clinicians, patients, consumers, or other users in selecting suitable off-the-shelf compression garments.

Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.

Abstract: Methods, devices, and systems for carotid body modulation via accessing a target site with an endovascular approach through a superficial temporal artery.

Abstract: A method for filtering blood including: withdrawing blood from an adult patient; performing ultrafiltration by filtering the withdrawn blood in a filter having an active filter membrane surface of no greater than 0.2 meters squared (m2) to remove ultrafiltrate from the blood, wherein the filter membrane blocks the passage of blood molecules having a molecular weight of at least 60,000 Daltons, wherein an amount of the removed ultrafiltrate is an effective therapeutic amount for treating a fluid overload condition of the patient; infusing the ultrafiltrated blood into the adult patient, and pumping the ultrafiltrate from the filter a rate no greater than one liter per hour.

Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.

Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.

Abstract: Methods and endovascular catheters for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via transmural carotid body ablation.

Abstract: A method to remove ascites from a mammalian body including: draining ascites from the peritoneal cavity to the bladder of the mammalian body, and evacuating the drained ascites out of the bladder. The method may be practiced with a valved fistula implanted into the bladder to form a passage between the peritoneal cavity and the bladder.

Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.

Abstract: Methods and cryogenic devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.

Abstract: Methods and percutaneous devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via percutaneous carotid body ablation.

Abstract: Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.

Abstract: Planning for and/or assessment of an ablation procedure on one or both carotid bodies or carotid body chemoreceptors or carotid body nerves to treat patients having a sympathetically mediated cardiac, metabolic, and pulmonary disease (e.g. hypertension, CHF, diabetes, sleep disordered breathing) resulting from peripheral chemoreceptor hypersensitivity, carotid body hyperactivity, high carotid body afferent nerve signaling or heightened sympathetic activation.

Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.

Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.